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Abstract: For hundreds of years, cancer has stumped medical professionals across the world as a cure evaded them. Now, a new approach 
to battling cancer has entered the arena: viruses. The concept of using one deadly disease to cure another has elevated cancer research 
to an entirely new level, with some promising results. This article examines recent research regarding the use of a modified measles virus 
in improving cancer outcomes. 
he first recorded case of cancer was documented around 
3000 BCE in ancient Egypt. Eight cases of breast tumors were 
documented in a textbook on trauma surgery.1 The textbook de-
scribed the removal process by cauterization using a fire drill. It 
also described the disease saying, “there is no treatment.”1 Since 
then, thousands of medical professionals and others have pro-
posed theories and treatments to try to outsmart the disease 
that alters the lives of millions throughout the world. Cancer is 
the second leading cause of mortality globally, responsible for 
one out of every six deaths.2 This means that for 17% of the pop-
ulation, a solution could not come soon enough. The battle 
against cancer has relied on utilizing many different toxins to 
directly target cancer cells, and is still one of the primary treat-
ments for cancer today. A new mindset on fighting cancer has 
entered the research world, and it focuses on modifying deadly 
viruses to target and kill cancer cells. While research on the use 
of viruses to treat cancer is still developing, promising results 
suggest that this therapy may prove useful in treating several 
types of cancer that have not responded to previous therapies. 
This article focuses on the measles virus for cancer treatment. 
The measles virus belongs to a family of viruses known 
as Paramyxoviridae, better known as a Morbillivirus or the kind 
of Paramyxoviridae that infects primates including humans.3 
Paramyxoviridae viruses are very infectious; they spread through 
the respiratory tract and can travel quickly throughout a 
population. It can cause significant immunosuppression, mor-
bidity, and mortality in the host.3 After the measles virus has en-
tered the respiratory tract, it infects cells of the respiratory path-
way or any nearby immune cells that it comes in contact with by 
binding to a specific cell receptor.4 Early signs of measles 
infection include high fever, rash covering most of the body, 
tiredness, and runny nose, with symptoms appearing anywhere 
from 7 to 14 days after exposure.4 Complications from the mea-
sles virus infection may range in severity from diarrhea to pneu-
monia, and tend to be more severe in adults or malnourished 
individuals.4 Measles infections remain one of the top killers of 
children throughout the world, resulting in 134,200 deaths in the 
year 2015 or 15 deaths every hour.5 However, the measles virus 
has been declared eliminated in the United States due to strong 
vaccination efforts.6  
 So how can a highly transmissible virus such as the 
measles virus be used to treat cancer? Typically, the genetically 
modified form of the measles virus used for cancer treatment 
binds to the CD46 receptor.7 This receptor is found on most all 
human cells, but tends to be expressed at a higher concentration 
on malignant tumors. Interestingly, developing research indi-
cates that the measles virus prefers to invade tissues that show 
a higher number of these receptors such as tumors.7 The mea-
sles virus spreads through the body primarily from a direct cell-
to-cell transfer including extremely immature cells, such as can-
cer cells.8 Once inside the cells, the measles virus causes the can-
cer cell membranes to fuse together and create giant cells, 
affecting the formation and replication of tumor cells.9  Most 
importantly, when the measles virus is inside the body, the 
infected person’s immune system is activated to try to fight the 
virus.9 One of the reasons cancer is so hard to beat is because it 
is composed of one’s own cells, and, therefore, the immune sys-
tem of the person with cancer does not recognize it as a target. 
However, when the measles virus enters the cancer cells, the 
body tends to respond to the virus by releasing powerful stimu-
lators of one’s own immune system.9 This is enough to trigger 
the body to try and get rid of the cancer cells, while in cases 
without the presence of a virus, it would not. Using the measles 
virus in this way has been investigated for a variety of cancers, 
including colon, ovarian, Non-Hodgkin Lymphoma, breast, pros-
tate, and pancreatic cancers.10 
When using a highly transmissible virus to treat cancer, 
safety must be considered first.  An important step in ensuring 
the safety of everyone involved requires the use of an altered 
form of the virus incapable of causing disease in normal human 
tissues, but still capable of triggering an immune response of the 
cancer-causing cells. This is known as an “attenuated virus,” and 
is similar to the state of a virus in vaccines. Beyond the use of an 
attenuated virus, there are two primary concerns for safety: the 
safety of the patient and the safety of the population.10 The 
attenuated measles virus proves effective in both areas. It is safe 
for the patient because it is genetically stable, tumor specific, 
and will not attack normal host tissues. It is safe for the 
population because it is largely non-transmissible in the United 
States since the population is generally immune due to vaccine 
prevalence. Furthermore, the measles virus has shown excellent 
consistency in its genetic coding, which is another key factor in 
determining the safety and stability of viruses for treatment. 
Some viruses, such as the influenza virus, which causes the flu, 
are considered “unstable.” The reason it is classified as such is 
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because the virus changes its genetic coding frequently, which 
explains the change in the flu vaccine from year to year. The 
measles virus, on the other hand, has essentially remained the 
same for several decades. This makes it incredibly unlikely that 
the attenuated virus administered to the patient for cancer 
treatment will revert back to a dangerous form of the virus, an 
important factor to consider when evaluating viruses for cancer 
treatment.10 
Before viruses are considered a viable option for cancer 
treatment, there are still many unknowns and questions that 
need to be answered. One of the biggest challenges researchers 
face is monitoring where the virus travels in the body after it is 
administered.11 It is important to track the virus in the body for 
several reasons, but one of the most important is to provide re-
searchers with information on how much of the virus is needed 
for treatment. Some evidence suggests that modifying a specific 
protein on the surface of the virus may provide a viable option. 
However, trying to find a non-invasive system for tracking the 
virus in the body has been a challenge. There is still much work 
needed in this area to improve tracking of the virus once in the 
body.11 
Although the use of the measles virus as a treatment 
for cancer looks promising, studies have been inconsistent. Clin-
ical trials completed so far have shown that the measles virus 
effectively eliminated cancer in only some cases.11 Furthermore, 
studies have found that the measles virus either did not affect 
the tumors at all or merely shrunk the tumors in size, but did not 
eliminate the tumor completely.11  Therefore, more research is 
warranted before the use of viruses becomes a widely accessible 
option for people with cancer, but what prevails provides a 
promising option. 
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